It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Recognition of pathogen-or-damage-associated molecular patterns is critical to inflammation. However, most pathogen-or-damage-associated molecular patterns exist within intact microbes/cells and are typically part of non-diffusible, stable macromolecules that are not optimally immunostimulatory or available for immune detection. Partial digestion of microbes/cells following phagocytosis potentially generates new diffusible pathogen-or-damage-associated molecular patterns, however, our current understanding of phagosomal biology would have these molecules sequestered and destroyed within phagolysosomes. Here, we show the controlled release of partially-digested, soluble material from phagolysosomes of macrophages through transient, iterative fusion-fission events between mature phagolysosomes and the plasma membrane, a process we term eructophagy. Eructophagy is most active in proinflammatory macrophages and further induced by toll like receptor engagement. Eructophagy is mediated by genes encoding proteins required for autophagy and can activate vicinal cells by release of phagolysosomally-processed, partially-digested pathogen associated molecular patterns. We propose that eructophagy allows macrophages to amplify local inflammation through the processing and dissemination of pathogen-or-damage-associated molecular patterns.
The detection of conserved motifs by pattern recognition receptors is a crucial component of the innate detection of pathogens and danger signals via conserved pattern recognition receptors. Here the authors define a pathway that transfers partially digested material from the phagolysosomal pathway of macrophages to release at the plasma membrane which is associated with enhanced inflammatory potential, by a process they introduce as eructophagy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University of Calgary, Department of Biochemistry and Molecular Biology, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
2 University of Calgary, Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
3 University of Calgary, Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Vir Biotechnology, San Francisco, USA (GRID:grid.507173.7)
4 Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
5 University of Calgary, Department of Biochemistry and Molecular Biology, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
6 Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Vir Biotechnology, San Francisco, USA (GRID:grid.507173.7)
7 University of Calgary, Department of Biochemistry and Molecular Biology, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Department of Comparative Biology and Experimental Medicine, Faculty of Veterinary Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); University of Calgary, Snyder Institute of Chronic Disease, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)